Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 229

1.

Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.

De Smaele E, Ferretti E, Gulino A.

Curr Opin Investig Drugs. 2010 Jun;11(6):707-18. Review.

PMID:
20496266
[PubMed - indexed for MEDLINE]
2.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.

PMID:
24259609
[PubMed - indexed for MEDLINE]
3.

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD.

Clin Cancer Res. 2011 Apr 15;17(8):2502-11. doi: 10.1158/1078-0432.CCR-10-2745. Epub 2011 Feb 7.

PMID:
21300762
[PubMed - indexed for MEDLINE]
Free Article
4.

Vismodegib in basal cell carcinoma.

Amaria RN, Bowles DW, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. Review.

PMID:
22844657
[PubMed - indexed for MEDLINE]
5.

Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Cirrone F, Harris CS.

Clin Ther. 2012 Oct;34(10):2039-50. doi: 10.1016/j.clinthera.2012.08.011. Epub 2012 Oct 1. Review.

PMID:
23036338
[PubMed - indexed for MEDLINE]
6.

Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.

Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA.

Clin Cancer Res. 2011 Sep 1;17(17):5774-82. doi: 10.1158/1078-0432.CCR-11-0972. Epub 2011 Jul 13.

PMID:
21753154
[PubMed - indexed for MEDLINE]
Free Article
7.

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.

Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, Gould SE.

Clin Cancer Res. 2011 Jul 15;17(14):4682-92. doi: 10.1158/1078-0432.CCR-11-0975. Epub 2011 May 24.

PMID:
21610148
[PubMed - indexed for MEDLINE]
Free Article
8.

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.

Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ.

J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1.

PMID:
24189279
[PubMed - indexed for MEDLINE]
Free Article
9.

Targeting the hedgehog pathway to treat basal cell carcinoma.

Geeraert P, Williams JS, Brownell I.

J Drugs Dermatol. 2013 May;12(5):519-23. Review.

PMID:
23652945
[PubMed - indexed for MEDLINE]
10.

GDC-0449--targeting the hedgehog signaling pathway.

Dierks C.

Recent Results Cancer Res. 2010;184:235-8. doi: 10.1007/978-3-642-01222-8_17. Review.

PMID:
20072843
[PubMed - indexed for MEDLINE]
11.

Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.

Dessinioti C, Plaka M, Stratigos AJ.

Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.

PMID:
24941979
[PubMed - indexed for MEDLINE]
12.

Clinical experience with Hedgehog pathway inhibitors.

Low JA, de Sauvage FJ.

J Clin Oncol. 2010 Dec 20;28(36):5321-6. doi: 10.1200/JCO.2010.27.9943. Epub 2010 Nov 1.

PMID:
21041712
[PubMed - indexed for MEDLINE]
Free Article
13.

Vismodegib.

Meiss F, Zeiser R.

Recent Results Cancer Res. 2014;201:405-17. doi: 10.1007/978-3-642-54490-3_25. Review.

PMID:
24756807
[PubMed - indexed for MEDLINE]
14.

Vismodegib for the treatment of basal cell skin cancer.

Poggi L, Kolesar JM.

Am J Health Syst Pharm. 2013 Jun 15;70(12):1033-8. doi: 10.2146/ajhp120311. Review.

PMID:
23719880
[PubMed - indexed for MEDLINE]
15.

Vismodegib: a promising drug in the treatment of basal cell carcinomas.

Dirix L, Rutten A.

Future Oncol. 2012 Aug;8(8):915-28. doi: 10.2217/fon.12.82.

PMID:
22894666
[PubMed - indexed for MEDLINE]
16.

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

Keating GM.

Drugs. 2012 Jul 30;72(11):1535-41. doi: 10.2165/11209590-000000000-00000. Review.

PMID:
22788238
[PubMed - indexed for MEDLINE]
17.

Hedgehog signaling pathway and cancer therapeutics: progress to date.

Ruch JM, Kim EJ.

Drugs. 2013 May;73(7):613-23. doi: 10.1007/s40265-013-0045-z. Review.

PMID:
23605693
[PubMed - indexed for MEDLINE]
18.

Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.

Lyseng-Williamson KA, Keating GM.

Am J Clin Dermatol. 2013 Feb;14(1):61-4. doi: 10.1007/s40257-012-0004-6.

PMID:
23329081
[PubMed - indexed for MEDLINE]
19.

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.

Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.

PMID:
19726788
[PubMed - indexed for MEDLINE]
Free Article
20.

Vismodegib.

Rudin CM.

Clin Cancer Res. 2012 Jun 15;18(12):3218-22. doi: 10.1158/1078-0432.CCR-12-0568. Epub 2012 Jun 7.

PMID:
22679179
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk